Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 49

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 49
---
 a bonus in the amount set forth in the table above.

With respect to Mr. Goeltz, key performance highlights included ongoing, real-time assessment of our budget and cash forecast throughout 2024, which allowed us to efficiently assess strategic decisions around clinical programs with a high degree of confidence. As part of this effort, Mr. Goeltz led a strategic planning exercise to align our broad portfolio of molecules and clinical trials against a scenario analysis, including timing and other critical variables, with the corresponding capital requirements. The results of the exercise enabled us to do a holistic evaluation of our plans and support our fund-raising strategy and efforts in 2024, leading to transactions that extended our cash runway in which Mr. Goeltz further played a seminal role in their tactical execution. Mr. Goeltz's leadership, strategic planning and foresight have been and continue to be critical to ensuring that we optimize the financial components and opportunities associated with our relationships with our multiple collaboration partners. Given the breadth of our portfolio of programs and the number of late-stage molecules and programs, these analyses were essential in creating operational plans that were prudent and efficient but also leveraged the opportunities inherent in the pipeline.

With respect to Dr. Jaen, key performance highlights included continued productivity of our discovery platform, including the advancement of new programs that are applicable to inflammatory disease and are central to the inflammation collaboration that we forged with Gilead in 2023. Dr. Jaen also led our translational efforts, which continued to generate data across our late-stage programs and are particularly important in linking the biology and mechanism of our molecules to their clinical activity. In the casdatifan program, his team generated data that established unambiguous differentiation from our major competitor in this field. Dr. Jaen continues to play the central role in bringing mechanism of action

<div align='center'>27.</div>

perspectives to decision making affecting our selections of combinations, settings and trial design across our portfolio of programs. Dr. Jaen also led our CMC efforts, which are unusually substantial and complicated for a company at our stage, given the number of late-stage trials that we have ongoing, as well as integrating the efforts and needs of our collaboration partners to optimize efficiency and cost.

With respect to Ms. Jarrett, key performance highlights included continued leadership of our corporate governance framework to enable the most efficient planning, decision-making and execution of our clinical development plan and integration of these efforts with our partners including Gilead, Taiho and AstraZeneca. These efforts were